These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15073471)

  • 1. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Saruta T; Kageyama S; Ogihara T; Hiwada K; Ogawa M; Tawara K; Gatlin M; Garthwaite S; Bittman R; Patrick J
    J Clin Hypertens (Greenwich); 2004 Apr; 6(4):175-83; quiz 184-5. PubMed ID: 15073471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
    Sato A; Fukuda S
    J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
    Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.